Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.00 | 21.20 | -0.23% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,442.56 | 4.87 | -0.01% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,471.86 | 110.79 | 0.42% |
| NASDAQ | 24,404.39 | 64.09 | -0.26% |
| Nikkei 225 | 59,499.84 | 674.95 | 1.15% |
| NZX 50 Index | 12,932.33 | 16.88 | 0.13% |
| S&P 500 | 7,109.14 | 16.92 | -0.24% |
| S&P/ASX 200 | 8,945.20 | 24.30 | -0.27% |
| SSE Composite Index | 4,079.44 | 2.69 | -0.07% |